Joel Greenblatt’s Catalyst Pharmaceutical CPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | – | Sell |
-41,216
| Closed | -$1.3M | – | 1891 |
|
|
2026
Q2 | $1.3M | Sell |
41,216
-20,155
| -33% | -$595K | ﹤0.01% | 1293 |
|
|
2026
Q1 | $1.52M | Sell |
61,371
-594
| -1% | -$14.2K | ﹤0.01% | 1188 |
|
|
2025
Q4 | $1.45M | Sell |
61,965
-79,378
| -56% | -$1.77M | 0.01% | 1145 |
|
|
2025
Q3 | $2.78M | Buy |
141,343
+31,618
| +29% | +$650K | 0.01% | 915 |
|
|
2025
Q2 | $2.38M | Buy |
109,725
+62,416
| +132% | +$1.47M | 0.01% | 870 |
|
|
2025
Q1 | $1.15M | Buy |
47,309
+8,356
| +21% | +$188K | 0.01% | 963 |
|
|
2024
Q4 | $813K | Buy |
38,953
+2,812
| +8% | +$60.4K | 0.01% | 971 |
|
|
2024
Q3 | $718K | Buy |
36,141
+2,444
| +7% | +$45.3K | 0.01% | 997 |
|
|
2024
Q2 | $522K | Sell |
33,697
-1,491
| -4% | -$23.2K | 0.01% | 1075 |
|
|
2024
Q1 | $561K | Sell |
35,188
-2,314
| -6% | -$34.9K | 0.01% | 1004 |
|
|
2023
Q4 | $630K | Sell |
37,502
-76,504
| -67% | -$1.05M | 0.01% | 920 |
|
|
2023
Q3 | $1.33M | Buy |
114,006
+3,532
| +3% | +$47.2K | 0.03% | 681 |
|
|
2023
Q2 | $1.48M | Sell |
110,474
-28,977
| -21% | -$417K | 0.03% | 641 |
|
|
2023
Q1 | $2.31M | Buy |
139,451
+120,406
| +632% | +$1.99M | 0.06% | 468 |
|
|
2022
Q4 | $354K | Sell |
19,045
-31,130
| -62% | -$479K | 0.01% | 999 |
|
|
2022
Q3 | $644K | Buy |
+50,175
| New | +$595K | 0.02% | 789 |
|
|
2020
Q4 | – | Sell |
-32,653
| Closed | -$97K | – | 1015 |
|
|
2020
Q3 | $97K | Sell |
32,653
-37,219
| -53% | -$146K | ﹤0.01% | 983 |
|
|
2020
Q2 | $323K | Sell |
69,872
-57,062
| -45% | -$256K | 0.01% | 847 |
|
|
2020
Q1 | $489K | Buy |
126,934
+90,420
| +248% | +$371K | 0.01% | 725 |
|
|
2019
Q4 | $137K | Sell |
36,514
-3,306
| -8% | -$15.5K | ﹤0.01% | 1065 |
|
|
2019
Q3 | $211K | Buy |
+39,820
| New | +$212K | ﹤0.01% | 1001 |
|
Other funds holding CPRX
Joel Greenblatt's CPRX Position: Q3 2026 in Review
Joel Greenblatt sold out of Catalyst Pharmaceutical (CPRX) in Q3 2026, closing a stake of 41,216 shares — an estimated $1.3M sold.
Joel Greenblatt first reported a position in CPRX in Q3 2019 and held it in 21 quarters. The position peaked at $2.78M in Q3 2025. 3 funds tracked by Wall St. Rank hold CPRX as of Q3 2026.
- Joel Greenblatt reported no remaining Catalyst Pharmaceutical position as of Q3 2026 after selling out during the quarter.
- Joel Greenblatt sold 41,216 Catalyst Pharmaceutical shares in Q3 2026, an estimated $1.3M.
- Joel Greenblatt first reported a position in Catalyst Pharmaceutical in Q3 2019 and held it in 21 quarters.
- Joel Greenblatt's Catalyst Pharmaceutical position peaked at $2.78M in Q3 2025.
- 3 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2026.
Based on Gotham Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.